Evaluation of iodine-123-labeled metaiodobenzylguanidine single- photon emission computed tomography/computed tomography based on the International Society of Pediatric Oncology Europe Neuroblastoma score in children with neuroblastoma

被引:3
作者
Zhou, Ziang [1 ]
Wang, Guanyun [1 ]
Qian, Luodan [1 ]
Liu, Jun [1 ]
Yang, Xu [1 ]
Zhang, Shuxin [1 ]
Zhang, Mingyu [1 ]
Kan, Ying [1 ]
Wang, Wei [1 ]
Yang, Jigang [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, 95 Yongan Rd, Beijing 100050, Peoples R China
基金
中国国家自然科学基金;
关键词
Metaiodobenzylguanidine (MIBG); single-photon emission computed tomography; computed tomography (SPECT; CT); neuroblastoma (NB); International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN); minimal residual disease (MRD); MINIMAL RESIDUAL DISEASE; BONE-MARROW; MIBG SCINTIGRAPHY; SPECT/CT; GUIDELINES; PREDICTOR; SURVIVAL; CRITERIA; MARKER; SCANS;
D O I
10.21037/qims-22-1120
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: This study sought to examine whether iodine-123-labeled metaiodobenzylguanidine (123I-MIBG) single-photon emission computed tomography/computed tomography (SPECT/CT), which is based on the International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) score, could improve the diagnostic efficiency of children with neuroblastoma (NB), and to compare the diagnostic ability of minimal residual disease (MRD) detection and 123I-MIBG SPECT/CT. Methods: We retrospectively analyzed 238 scans of patients who underwent 123I-MIBG SPECT/CT at the Department of Nuclear Medicine, Beijing Friendship Hospital, from January 2021 to December 2021. The diagnostic study was not registered with a clinical trial platform, and the study protocol was not published. The standard was established based on pathology, other relevant imaging examinations, and follow-up. The SIOPEN scores were calculated separately based on planar and tomographic imaging. Results: In a comparison to the standard mentioned in the method, the diagnostic accuracy of planar and tomographic imaging was 151 of 238 (63.5%) and 228 of 238 (95.8%), respectively, and the kappa values of the SIOPEN score were 0.468 and 0.855 (P<0.001), respectively. The SIOPEN scores differed significantly among the various subgroups. The polymerase chain reaction (PCR) method used to detect the bone marrow PHOX2B gene was able to find bone/bone marrow metastases (P=0.024, kappa=0.282), while the flow cytometry (FCM) assay method was not statistically significant (P=0.417, kappa=0.065). Conclusions: 123I-MIBG SPECT/CT, which relies on the semiquantitative assessment of the SIOPEN score, is of clinical importance in the management of pediatric NB. MRD detection can be used to detect early metastasis and recurrence in the bone or bone marrow; however, 123I-MIBG SPECT/CT has better diagnostic value. We intend to conduct further investigations on their prognostic value in the future.
引用
收藏
页码:3841 / 3851
页数:11
相关论文
共 37 条
[1]   Guidelines on nuclear medicine imaging in neuroblastoma [J].
Bar-Sever, Zvi ;
Biassoni, Lorenzo ;
Shulkin, Barry ;
Kong, Grace ;
Hofman, Michael S. ;
Lopci, Egesta ;
Manea, Irina ;
Koziorowski, Jacek ;
Castellani, Rita ;
Boubaker, Ariane ;
Lambert, Bieke ;
Pfluger, Thomas ;
Nadel, Helen ;
Sharp, Susan ;
Giammarile, Francesco .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (11) :2009-2024
[2]   Detecting minimal residual disease in neuroblastoma patients - the present state of the art [J].
Beiske, K ;
Ambros, PF ;
Burchill, SA ;
Cheung, IY ;
Swerts, K .
CANCER LETTERS, 2005, 228 (1-2) :229-240
[3]   Minimal residual disease testing in hematologic malignancies and solid cancer [J].
Ben Lassoued, Amin ;
Nivaggioni, Vanessa ;
Gabert, Jean .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (06) :699-712
[4]   131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging [J].
Bombardieri, Emilio ;
Giammarile, Francesco ;
Aktolun, Cumali ;
Baum, Richard P. ;
Delaloye, Angelika Bischof ;
Maffioli, Lorenzo ;
Moncayo, Roy ;
Mortelmans, Luc ;
Pepe, Giovanna ;
Reske, Sven N. ;
Castellani, Maria R. ;
Chiti, Arturo .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (12) :2436-2446
[5]   Recommendations for the Standardization of Bone Marrow Disease Assessment and Reporting in Children With Neuroblastoma on Behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group [J].
Burchill, Susan A. ;
Beiske, Klaus ;
Shimada, Hiroyuki ;
Ambros, Peter F. ;
Seeger, Robert ;
Tytgat, Godelieve A. M. ;
Brock, Penelope R. ;
Haber, Michelle ;
Park, Julie R. ;
Berthold, Frank .
CANCER, 2017, 123 (07) :1095-1105
[6]   Bone Marrow Minimal Residual Disease Was an Early Response Marker and a Consistent Independent Predictor of Survival After Anti-GD2 Immunotherapy [J].
Cheung, Nai-Kong V. ;
Ostrovnaya, Irina ;
Kuk, Deborah ;
Cheung, Irene Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) :755-763
[7]   Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study [J].
Decarolis, Boris ;
Schneider, Christina ;
Hero, Barbara ;
Simon, Thorsten ;
Volland, Ruth ;
Roels, Frederik ;
Dietlein, Markus ;
Berthold, Frank ;
Schmidt, Matthias .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) :944-951
[8]   Comparison of Diagnostic Value of I-123 MIBG and High-Dose I-131 MIBG Scintigraphy Including Incremental Value of SPECT/CT Over Planar Image in Patients With Malignant Pheochromocytoma/Paraganglioma and Neuroblastoma [J].
Fukuoka, Makoto ;
Taki, Junichi ;
Mochizuki, Takafumi ;
Kinuya, Seigo .
CLINICAL NUCLEAR MEDICINE, 2011, 36 (01) :1-7
[9]  
GELFAND MJ, 1994, J NUCL MED, V35, P1753
[10]   Minimal residual disease in multiple myeloma: use of magnetic resonance imaging [J].
Hillengass, Jens ;
Merz, Maximilian ;
Delorme, Stefan .
SEMINARS IN HEMATOLOGY, 2018, 55 (01) :19-21